Among patients with resected stage 3B to 4 melanoma, postsurgical treatment with Opdivo (nivolumab) was associated with a ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") announced that ONO-4578, an EP4 antagonist, in combination with Opdivo, an anti–PD-1 antibody and ...

The Chinorec trial reveals that combining Yervoy and Opdivo with chemoradiotherapy is safe for rectal cancer, though response rates remain unchanged.

Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on ...

Bristol Myers Squibb Co said on Wednesday its cancer drug Opdivo plus chemotherapy helped more patients with a form of lung cancer become free of the disease versus chemotherapy alone in a late-stage ...

In the phase 1 clinical trial (NCT03155061) 3 in patients with unresectable advanced or recurrent gastric cancer, including gastroesophageal junction cancer, the combination of ONO-4578 and nivolumab ...

Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untreated patients with advanced kidney cancer, ...

Two common immunotherapy drugs will now be subsidised for all advanced or metastatic cancers, providing a lifeline to ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has granted approval to ...